Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 6/20 | 0.45 |
| ▸ | AHCY | P23526 | 3/20 | 0.41 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.38 |
| ▸ | GNMT | Q14749 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | PI4KA | P42356 | 1/20 | 0.36 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | ADCY5 | O95622 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21311397 | 0.93 | DOT1L (0.43) | DOT1LAHCYCARM1ADORA2API4KA | |
| SCHEMBL21311157 | 0.86 | PI4KA (0.41) | DOT1LAHCYCARM1ADORA2API4KA | |
| SCHEMBL21311156 | 0.86 | ADORA2A (0.40) | DOT1LAHCYADORA2API4KAPI4K2B | |
| SCHEMBL21311391 | 0.86 | ADORA2A (0.43) | DOT1LAHCYCARM1ADORA2API4KA | |
| SCHEMBL21311158 | 0.78 | HTT (0.41) | DOT1LADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL20097216 | 0.75 | DOT1L (0.58) | DOT1LAHCYCARM1GNMTNT5E | |
| SCHEMBL21311195 | 0.69 | EGFR (0.44) | DOT1LAHCYCARM1GNMTEGFR | |
| SCHEMBL20096666 | 0.68 | DOT1L (0.56) | DOT1LAHCYCARM1NT5E | |
| SCHEMBL26828674 | 0.67 | ADORA3 (0.49) | DOT1LAHCYADORA2API4KAPI4K2B | |
| SCHEMBL8704526 | 0.67 | AHCY (0.47) | DOT1LAHCYADORA2API4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190262371-A1 | METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190262371-A1 | METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS | POLRMT, EIF2AK2, NSUN3 | DOT1L 2274/4885AHCY 1888/4885CARM1 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.